Why Jounce Therapeutics Stock Is Crashing Today

Shares of Jounce Therapeutics (NASDAQ: JNCE) were crashing 20.2% lower as of 11:42 a.m. EST on Monday. The big drop came after the company announced that it would not continue patient enrollment in the Emerge phase 2 trial evaluating vopratelimab (vopra) in combination with Bristol Myers Squibb's Yervoy in treating non-small cell lung cancer (NSCLC). 

Jounce stated that early analysis of the data from the Emerge phase 2 study indicated that "the trial will not meet pre-specified interim criteria for continuation of enrollment." As a result, the biotech said that it wouldn't expand enrollment in the Emerge clinical trial as originally planned.

Image source: Getty Images.

Continue reading

Source Fool.com